Can a common drug boost Chemo's power against Hard-to-Treat leukemia?
NCT ID NCT07766850
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This trial is testing whether adding hydroxyurea to a standard chemotherapy combination can improve outcomes for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The study is conducted in two parts: first to find the safest dose of hydroxyurea, then to see if it helps keep the disease from progressing. Participants receive hydroxyurea alongside fludarabine, cytarabine, idarubicin, and venetoclax, with the goal of improving event-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hydroxyurea added to a combination of fludarabine, cytarabine, idarubicin, and venetoclax
- What this could lead to
- If successful, this could offer a new, more effective treatment option for adults with AML that has returned or not responded to prior therapy, potentially extending the time without disease progression.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not hold in larger groups. Adding hydroxyurea could increase side effects, and the benefit over standard treatment is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Unit Hematology, Karolinska University Hospital
Stockholm, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.